Depression and suicidality in COPD: Understandable reaction or independent disorders?

European Respiratory Journal

Volumn 44, Issue 3, 2014, Pages 734-743

  Hegerl, Ulrich ^a   Mergl, Roland ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; DIAZEPAM; DOXEPIN; FLUOXETINE; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG OVERDOSE; EVIDENCE BASED MEDICINE; HIGH RISK BEHAVIOR; HUMAN; LIFE EXPECTANCY; LUNG FUNCTION; MAJOR DEPRESSION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUICIDAL BEHAVIOR; SYMPTOMATOLOGY; TREATMENT OUTCOME; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; PSYCHOLOGY; RISK FACTOR; SUICIDE; SWEDEN;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; HUMANS; PREVALENCE; PSYCHOTHERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK FACTORS; SUICIDE; SWEDEN;

EID: 84907301768     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00193213     Document Type: Review

References (70)

1. Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002-2030. Ann Trop Med Parasitol 2006; 100: 481-499.
2. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 655-679.
3. Atlantis E, Fahey P, Cochrane B, et al. Bidirectional associations between clinically relevant depression or anxiety and chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. Chest 2013; 144: 766-777.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edn. Arlington, American Psychiatric Association, 2013.
5. Cavanagh JT, Carson AJ, Sharpe M, et al. Psychological autopsy studies of suicide: a systematic review. Psychol Med 2003; 33: 395-405.
6. Leucht S, Hierl S, Kissling W, et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012; 200: 97-106.
7. Baraniak A, Sheffield D. The efficacy of psychologically based interventions to improve anxiety, depression and quality of life in COPD: a systematic review and meta-analysis. Patient Educ Couns 2011; 83: 29-36.
8. Cafarella PA, Effing TW, Usmani ZA, et al. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology 2012; 17: 627-638.
9. Coventry PA, Gellatly JL. Improving outcomes for COPD patients with mild-to-moderate anxiety and depression: a systematic review of cognitive behavioural therapy. Br J Health Psychol 2008; 13: 381-400.
10. Fritzsche A, Clamor A, von Leupoldt A. Effects of medical and psychological treatment of depression in patients with COPD - a review. Respir Med 2011; 105: 1422-1433.
11. Putman-Casdorph H, McCrone S. Chronic obstructive pulmonary disease, anxiety, and depression: state of the science. Heart Lung 2009; 38: 34-47.
12. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
13. Yohannes AM, Willgoss TG, Baldwin RC, et al. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry 2010; 25: 1209-1221.
14. Linden M, Muschalla B. Standardized diagnostic interviews, criteria, and algorithms for mental disorders: garbage in, garbage out. Eur Arch Psychiatry Clin Neurosci 2012; 262: 535-544.
15. Joshi M, Joshi A, Bartter T. Symptom burden in chronic obstructive pulmonary disease and cancer. Curr Opin Pulm Med 2012; 18: 97-103.
16. Hegerl U, Lam RW, Malhi GS, et al. Conceptualising the neurobiology of fatigue. Aust N Z J Psychiatry 2013; 47: 312-316.
17. Hegerl U, Wilk K, Olbrich S, et al. Hyperstable regulation of vigilance in patients with major depressive disorder. World J Biol Psychiatry 2012; 13: 436-446.
18. van Ede L, Yzermans CJ, Brouwer HJ. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. Thorax 1999; 54: 688-692.
19. Zhang MW, Ho RC, Cheung MW, et al. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry 2011; 33: 217-223.
20. McSweeny AJ, Grant I, Heaton RK, et al. Life quality of patients with chronic obstructive pulmonary disease. Arch Intern Med 1982; 142: 473-478.
21. Prigatano GP, Wright EC, Levin D. Quality of life and its predictors in patients with mild hypoxemia and chronic obstructive pulmonary disease. Arch Intern Med 1984; 144: 1613-1619.
22. De S. Prevalence of depression in stable chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 2011; 53: 35-39.
23. Hayashi Y, Senjyu H, Iguchi A, et al. Prevalence of depressive symptoms in Japanese male patients with chronic obstructive pulmonary disease. Psychiatry Clin Neurosci 2011; 65: 82-88.
24. Goodwin RD, Lavoie KL, Lemeshow AR, et al. Depression, anxiety, and COPD: the unexamined role of nicotine dependence. Nicotine Tob Res 2012; 14: 176-183.
25. Joo H, Park J, Lee SD, et al. Comorbidities of chronic obstructive pulmonary disease in Koreans: a populationbased study. J Korean Med Sci 2012; 27: 901-906.
26. Loerbroks A, Jiang CQ, Thomas GN, et al. COPD and depressive symptoms: findings from the Guangzhou Biobank Cohort Study. Ann Behav Med 2012; 44: 408-415.
27. Lou P, Zhu Y, Chen P, et al. Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study. BMC Pulm Med 2012; 12: 53.
28. Marinho PE, Castro CM, Raposo MC, et al. Depressive symptoms, inflammatory markers and body composition in elderly with and without chronic obstructive pulmonary disease (COPD). Arch Gerontol Geriatr 2012; 54: 453-458.
29. Obradovic LM, Pesut DP, Maric D, et al. Symptoms of anxiety and depression in patients with chronic obstructive pulmonary disease. Pneumologia 2012; 61: 92-96.
30. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012; 12: 26.
31. Arimura Y, Yamazaki S, Yanagi S, et al. Clinical usefulness of the two-question assessment tool for depressive symptoms in Japanese patients with chronic obstructive pulmonary disease. Lung 2013; 191: 101-107.
32. Horita N, Kaneko T, Shinkai M, et al. Depression in Japanese patients with chronic obstructive pulmonary disease: a cross-sectional study. Respir Care 2013; 58: 1196-1203.
33. Iguchi A, Senjyu H, Hayashi Y, et al. Relationship between depression in patients with COPD and the percent of predicted FEV1, BODE index, and health-related quality of life. Respir Care 2013; 58: 334-339.
34. Lee YS, Park S, Oh YM, et al. Chronic obstructive pulmonary disease assessment test can predict depression: a prospective multi-center study. J Korean Med Sci 2013; 28: 1048-1054.
35. Papaioannou AI, Bartziokas K, Tsikrika S, et al. The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations. Eur Respir J 2013; 41: 815-823.
36. Qian J, Simoni-Wastila L, Langenberg P, et al. Effects of depression diagnosis and antidepressant treatment on mortality in Medicare beneficiaries with chronic obstructive pulmonary disease. J Am Geriatr Soc 2013; 61: 754-761.
37. Sharma BB, Singh S, Sharma VK, et al. Psychiatric morbidity in chronic respiratory disorders in an Indian service using GMHAT/PC. Gen Hosp Psychiatry 2013; 35: 39-44.
38. Warmenhoven F, Bor H, Lucassen P, et al. Depressive disorder in the last phase of life in patients with cardiovascular disease, cancer, and COPD: data from a 20-year follow-up period in general practice. Br J Gen Pract 2013; 63: e303-e308.
39. Zhang L, Lou P, Zhu Y, et al. Impact of risk factors, activities and psychological disorders on the health of patients with chronic obstructive pulmonary disease in China: a cross-sectional study. BMC Public Health 2013; 13: 627.
40. Gabilondo A, Vilagut G, Pinto-Meza A, et al. Comorbidity of major depressive episode and chronic physical conditions in Spain, a country with low prevalence of depression. Gen Hosp Psychiatry 2012; 34: 510-517.
41. Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123: 1684-1692.
42. Crump C, Sundquist K, Sundquist J, et al. Sociodemographic, psychiatric and somatic risk factors for suicide: a Swedish national cohort study. Psychol Med 2014; 44: 279-289.
43. Goodwin RD. Is COPD associated with suicide behavior? J Psychiatr Res 2011; 45: 1269-1271.
44. Webb RT, Kontopantelis E, Doran T, et al. Suicide risk in primary care patients with major physical diseases: a casecontrol study. Arch Gen Psychiatry 2012; 69: 256-264.
45. Yildirim A, Aşilar RH, Bakar N, et al. Effect of anxiety and depression on self-care agency and quality of life in hospitalized patients with chronic obstructive pulmonary disease: a questionnaire survey. Int J Nurs Pract 2013; 19: 14-22.
46. Hanania NA, Müllerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011; 183: 604-611.
47. García-Polo C, Alcázar-Navarrete B, Ruiz-Iturriaga LA, et al. Factors associated with high healthcare resource utilisation among COPD patients. Respir Med 2012; 106: 1734-1742.
48. Ito K, Kawayama T, Shoji Y, et al. Depression, but not sleep disorder, is an independent factor affecting exacerbations and hospitalization in patients with chronic obstructive pulmonary disease. Respirology 2012; 17: 940-949.
49. Cuijpers P, van Straten A, van Oppen P, et al. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry 2008; 69: 1675-1685.
50. Carreiro A, Santos J, Rodrigues F. Impact of comorbidities in pulmonary rehabilitation outcomes in patients with chronic obstructive pulmonary disease. Rev Port Pneumol 2013; 19: 106-113.
51. Turan O, Yemez B, Itil O. The effects of anxiety and depression symptoms on treatment adherence in COPD patients. Prim Health Care Res Dev 2014; 15: 244-251.
52. Light RW, Merrill EJ, Despars J, et al. Doxepin treatment of depressed patients with chronic obstructive pulmonary disease. Arch Intern Med 1986; 146: 1377-1380.
53. Sharma TN, Goyal RL, Gupta PR, et al. Psychiatric disorders in COPD with special reference to the usefulness of imipramine-diazepam combination. Indian J Chest Dis Allied Sci 1988; 30: 263-268.
54. Borson S, McDonald GJ, Gayle T, et al. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992; 33: 190-201.
55. Silvertooth EJ, Doraiswamy PM, Clary GL, et al. Citalopram and quality of life in lung transplant recipients. Psychosomatics 2004; 45: 271-272.
56. Yohannes AM, Connolly MJ, Baldwin RC. A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry 2001; 16: 451-454.
57. Lacasse Y, Beaudoin L, Rousseau L, et al. Randomized trial of paroxetine in end-stage COPD. Monaldi Arch Chest Dis 2004; 61: 140-147.
58. Eiser N, Harte R, Spiros K, et al. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD 2005; 2: 233-241.
59. DGPPN. S3 Guideline/National Guideline for Care of Unipolar Depression: Long version. [S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression: Langfassung]. Version 1.3. Berlin, Düsseldorf, DGPPN, ÄZQ, AWMF, 2012.
60. National Institute for Health and Clinical Excellence. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care (Partial Update). NICE Clinical Guideline 101. London, NICE, 2010.
61. National Institute for Health and Care Excellence. Depression in Adults with a Chronic Physical Health Problem: Treatment and Management. NICE Clinical Guideline 91. London, NICE, 2009.
62. Hynninen MJ, Bjerke N, Pallesen S, et al. A randomized controlled trial of cognitive behavioral therapy for anxiety and depression in COPD. Respir Med 2010; 104: 986-994.
63. Coventry PA, Bower P, Keyworth C, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One 2013; 8: e60532.
64. Kunik ME, Veazey C, Cully JA, et al. COPD education and cognitive behavioral therapy group treatment for clinically significant symptoms of depression and anxiety in COPD patients: a randomized controlled trial. Psychol Med 2008; 38: 385-396.
65. Schneider C, Jick SS, Bothner U, et al. COPD and the risk of depression. Chest 2010; 137: 341-347.
66. Roth T. Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Sleep Med 2009; 10: 19-25.
67. Stege G, Vos PJ, van den Elshout FJ, et al. Sleep, hypnotics and chronic obstructive pulmonary disease. Respir Med 2008; 102: 801-814.
68. George CF, Bayliff CD. Management of insomnia in patients with chronic obstructive pulmonary disease. Drugs 2003; 63: 379-387.
69. Larsen J, Arnberg A, Brøsen K. Tramadol og oxazepam. Effekt pa lungefunktionen hos aeldre patienter med kronisk obstruktiv lungesygdom [Tramadol and oxazepam. Effect on pulmonary function in elderly patients with chronic obstructive lung disease]. Ugeskr Laeger 2001; 163: 458-460.
70. Tolin DF. Is cognitive-behavioral therapy more effective than other therapies? A meta-analytic review. Clin Psychol Rev 2010; 30: 710-720.